"Additionally, Cynata is responding to enquiries and is in active discussions with international pharmaceutical
companies and other parties about the potential of its Cymerus MSCs to be a useful adjunct in the management of
patients with serious and ongoing issues associated with COVID-19 infection."
Ann: Market Update & Additional A$618k R&D Tax Refund, page-2
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.11M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.0¢ | 24.0¢ | $13.25K | 55.23K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 38280 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 42716 | 2 |
View Market Depth
| Last trade - 13.39pm 14/05/2024 (20 minute delay) ? |
| CYP (ASX) Chart |